🚀 VC round data is live in beta, check it out!
OSE Immunotherapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for OSE Immunotherapeutics and similar public comparables like Fractyl Health, Cinclus Pharma Holding, OKYO Pharma, Eco Animal Health Group and more.
OSE Immunotherapeutics Overview
About OSE Immunotherapeutics
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
Founded
2016
HQ
Employees
40
Website
Sectors
Financials (LTM)
EV
$85M
OSE Immunotherapeutics Financials
OSE Immunotherapeutics reported last 12-month revenue of $18M and negative EBITDA of ($16M).
In the same LTM period, OSE Immunotherapeutics generated $18M in gross profit, ($16M) in EBITDA losses, and had net loss of ($20M).
Revenue (LTM)
OSE Immunotherapeutics P&L
In the most recent fiscal year, OSE Immunotherapeutics reported revenue of $86M and EBITDA of $55M.
OSE Immunotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $18M | XXX | $86M | XXX | XXX | XXX |
| Gross Profit | $18M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($16M) | XXX | $55M | XXX | XXX | XXX |
| EBITDA Margin | (89%) | XXX | 64% | XXX | XXX | XXX |
| EBIT Margin | (106%) | XXX | 57% | XXX | XXX | XXX |
| Net Profit | ($20M) | XXX | $46M | XXX | XXX | XXX |
| Net Margin | (106%) | XXX | 54% | XXX | XXX | XXX |
| Net Debt | — | — | $31M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
OSE Immunotherapeutics Stock Performance
OSE Immunotherapeutics has current market cap of $88M, and enterprise value of $85M.
Market Cap Evolution
OSE Immunotherapeutics' stock price is $3.84.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $85M | $88M | 2.3% | XXX | XXX | XXX | $2.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOSE Immunotherapeutics Valuation Multiples
OSE Immunotherapeutics trades at 4.6x EV/Revenue multiple, and (5.2x) EV/EBITDA.
EV / Revenue (LTM)
OSE Immunotherapeutics Financial Valuation Multiples
As of April 18, 2026, OSE Immunotherapeutics has market cap of $88M and EV of $85M.
Equity research analysts estimate OSE Immunotherapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OSE Immunotherapeutics has a P/E ratio of (4.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $88M | XXX | $88M | XXX | XXX | XXX |
| EV (current) | $85M | XXX | $85M | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | (5.2x) | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBIT | (4.3x) | XXX | 1.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | — | XXX | XXX | XXX |
| P/E | (4.5x) | XXX | 1.9x | XXX | XXX | XXX |
| EV/FCF | (4.9x) | XXX | 1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified OSE Immunotherapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
OSE Immunotherapeutics Margins & Growth Rates
OSE Immunotherapeutics' revenue in the last 12 month declined by (35%).
OSE Immunotherapeutics' revenue per employee in the last FY averaged $2.1M, while opex per employee averaged $1.2M for the same period.
OSE Immunotherapeutics' rule of 40 is (292%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OSE Immunotherapeutics' rule of X is (369%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
OSE Immunotherapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (35%) | XXX | (75%) | XXX | XXX | XXX |
| EBITDA Margin | (89%) | XXX | 64% | XXX | XXX | XXX |
| EBITDA Growth | 54% | XXX | (123%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (292%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (369%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 161% | XXX | 42% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
OSE Immunotherapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| OSE Immunotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Fractyl Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Cinclus Pharma Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| OKYO Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Eco Animal Health Group | XXX | XXX | XXX | XXX | XXX | XXX |
| PolyPid | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OSE Immunotherapeutics M&A Activity
OSE Immunotherapeutics acquired XXX companies to date.
Last acquisition by OSE Immunotherapeutics was on XXXXXXXX, XXXXX. OSE Immunotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by OSE Immunotherapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOSE Immunotherapeutics Investment Activity
OSE Immunotherapeutics invested in XXX companies to date.
OSE Immunotherapeutics made its latest investment on XXXXXXXX, XXXXX. OSE Immunotherapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by OSE Immunotherapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout OSE Immunotherapeutics
| When was OSE Immunotherapeutics founded? | OSE Immunotherapeutics was founded in 2016. |
| Where is OSE Immunotherapeutics headquartered? | OSE Immunotherapeutics is headquartered in France. |
| How many employees does OSE Immunotherapeutics have? | As of today, OSE Immunotherapeutics has over 40 employees. |
| Is OSE Immunotherapeutics publicly listed? | Yes, OSE Immunotherapeutics is a public company listed on Euronext Paris. |
| What is the stock symbol of OSE Immunotherapeutics? | OSE Immunotherapeutics trades under OSE ticker. |
| When did OSE Immunotherapeutics go public? | OSE Immunotherapeutics went public in 2015. |
| Who are competitors of OSE Immunotherapeutics? | OSE Immunotherapeutics main competitors are Fractyl Health, Cinclus Pharma Holding, OKYO Pharma, Eco Animal Health Group. |
| What is the current market cap of OSE Immunotherapeutics? | OSE Immunotherapeutics' current market cap is $88M. |
| What is the current revenue of OSE Immunotherapeutics? | OSE Immunotherapeutics' last 12 months revenue is $18M. |
| What is the current revenue growth of OSE Immunotherapeutics? | OSE Immunotherapeutics revenue growth (NTM/LTM) is (35%). |
| What is the current EV/Revenue multiple of OSE Immunotherapeutics? | Current revenue multiple of OSE Immunotherapeutics is 4.6x. |
| Is OSE Immunotherapeutics profitable? | No, OSE Immunotherapeutics is not profitable. |
| What is the current EBITDA of OSE Immunotherapeutics? | OSE Immunotherapeutics has negative EBITDA and is not profitable. |
| What is OSE Immunotherapeutics' EBITDA margin? | OSE Immunotherapeutics' last 12 months EBITDA margin is (89%). |
| What is the current EV/EBITDA multiple of OSE Immunotherapeutics? | Current EBITDA multiple of OSE Immunotherapeutics is (5.2x). |
| What is the current FCF of OSE Immunotherapeutics? | OSE Immunotherapeutics' last 12 months FCF is ($17M). |
| What is OSE Immunotherapeutics' FCF margin? | OSE Immunotherapeutics' last 12 months FCF margin is (93%). |
| What is the current EV/FCF multiple of OSE Immunotherapeutics? | Current FCF multiple of OSE Immunotherapeutics is (4.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.